By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Focuses on applying our expertise to develop novel drug candidates11.79M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
Rest of world97.05M98.60%
United States1.38M1.40%